American Heart Journal
Volume 152, Issue 4 , Pages 636-640 , October 2006

Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: Rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial

  • Jan Paul Ottervanger, MD, PhD, FESC

      Affiliations

    • Isala klinieken, Zwolle, The Netherlands
    • Corresponding Author InformationReprint requests: Jan Paul Ottervanger, MD, PhD, FESC, Isala klinieken, Locatie Weezenlanden, Department of Cardiology, Groot Wezenland 20, 8011 JW Zwolle, The Netherlands.
    • ,
  • Anand R. Ramdat Misier, PhD

      Affiliations

    • Isala klinieken, Zwolle, The Netherlands
    • ,
  • Felix Zijlstra, PhD

      Affiliations

    • University Medical Center Groningen, University of Groningen, The Netherlands
    • ,
  • Martin J. Schalij, PhD

      Affiliations

    • University Hospital, Leiden, The Netherlands
    • ,
  • Eric Wever, PhD

      Affiliations

    • Antonius Hospital, Nieuwegein, The Netherlands
    • ,
  • Luc J.L.M. Jordaens, PhD

      Affiliations

    • Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Jose P.S. Henriques, PhD

      Affiliations

    • Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Menko-Jan de Boer, PhD

      Affiliations

    • Isala klinieken, Zwolle, The Netherlands
    • ,
  • Hindrik W.J. Robbe, PhD

      Affiliations

    • Medtronic, Heerlen, The Netherlands
    • Dr Robbe is an employee of Medtronic, Heerlen, The Netherlands.
    • ,
  • Hein J.J. Wellens, PhD

      Affiliations

    • University Hospital, Maastricht, The Netherlands
    • ,
  • for the DAPA Investigators

Received 5 October 2005 ,Accepted 16 June 2006.

References 

  1. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525–530
  2. Domanski MJ, Exner DV, Borkow CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol. 1999;33:598–604
  3. Teo KK, Mitchell LB, Pogue J, et al. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure and left ventricular dysfunction. Circulation. 2004;110:1413–1417
  4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717
  5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  6. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med. 1996;335:1933–1940
  7. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced heart failure. N Engl J Med. 2004;350:2140–2150
  8. Bardy GH, Lee KL, Mark DB, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  9. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47–57
  10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20
  11. Yap YG, Duong T, Bland M, et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J. 2005;14:1385–1393
  12. De Luca G, van 't Hof AWJ, Ottervanger JP, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J. 2005;26:662–666
  13. De Luca G, Suryapranata H, Dambrink JHE, et al. Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J. 2004;148:852–856
  14. Mehta RH, Harjai KJ, Cox D, et al. Primary angioplasty in myocardial infarction (PAMI) investigators. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1739–1746
  15. Haager PK, Christott P, Heussen N, et al. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol. 2003;41:532–538
  16. Henriques JPS, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1076–1078
  17. Fath-Ordoubadi F, Huehns T, Al-Mohammad A, et al. Significance of the thrombolysis in myocardial infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J. 1997;134:62–68
  18. Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. Circulation. 1998;97:1549–1556
  19. Gibson CM, Cannon CP, Murphy SA, et al. for the European Cooperative Study Group Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–130
  20. Lenderink T, Simoons ML, Es van G, et al. for the European Cooperative Study Group Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 1995;92:1110–1116
  21. Lincoff AM, Topol EJ, Califf RM, et al. for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow “patency” (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Am J Cardiol. 1995;75:871–876
  22. Anderson JL, Karagounis LA, Califf RM. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol. 1996;78:1–8
  23. Cura FA, L'Allier PL, Kapadia SR, et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2001;88:124–128
  24. Simoons ML, Vos J, Tijssen JGP, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol. 1989;14:1609–1615
  25. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005;45:1397–1405
  26. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  27. Hohnloser SH, Kick KH, Dorian P, et al. Randomized trial of prophylactic implantable cardioverter defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  28. Wilber DJ, Zareba W, Hall WJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082–1084
  29. Richter S, Duray G, Gronefeld G, et al. Prevention of sudden cardiac death. Lessons from recent controlled trials. Circ J. 2005;69:625–629
  30. Elhendy A, Chapman S, Porter TR, et al. Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J Am Coll Cardiol. 2005;46:1721–1726
  31. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators . Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569–1575
  32. Bigger JT, Whang W, Rottman JN, et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation. 1999;99:1416–1421
  33. Dorian P, Connolly S, Hohnloser SH. Why don't ICDS decrease all-cause mortality after MI? Insights from the DINAMIT study (abstract). Circulation. 2004;110(Suppl III):III-502
  34. Gronefeld G, Thorpe KE, Connolly SJ, et al. Competing risks for arrhythmic versus non-arrhythmic death in prophylactic ICD therapy early after myocardial infarction (abstract). Circulation. 2004;110(Suppl III):III-502
  35. The GUSTO Angiographic Investigators . The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival, after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622
  36. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142–154
  37. de Boer MJ, Reiber JHC, Suryapranata H, et al. Angiographic findings and catheterisation laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J. 1995;16:1347–1356
  38. van der Horst IC, Zijlstra F, van 't Hof AWJ, et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol. 2003;42:784–791
  39. Snapinn SM. Monitoring clinical trials with a conditional probability stopping rule. Stat Med. 1992;11:659–672

PII: S0002-8703(06)00560-6

doi: 10.1016/j.ahj.2006.06.012

American Heart Journal
Volume 152, Issue 4 , Pages 636-640 , October 2006

Article Tools